natgillin/translations-raw huggingface dataset:
The following adverse reactions have been reported during post-marketing surveillance.
Sljedeće nuspojave prijavljene su tijekom praćenja nuspojava nakon stavljanja lijeka u promet.
The following adverse reactions have been reported in clinical studies involving 18 patients treated with Coagadex.
Sljedeće nuspojave prijavljene su u kliničkim ispitivanjima koja uključuju 18 bolesnika liječenih lijekom Coagadex.
The following adverse reactions have been reported post-marketing in temporal association with the use of Xarelto.
Nakon stavljanja lijeka u promet prijavljene su sljedeće nuspojave vremenski povezane s primjenom lijeka Xarelto.
The following adverse reactions have been reported to have a causal association with lapatinib alone or lapatinib in combination with capecitabine, trastuzumab or letrozole.
Prijavljene su sljedeće nuspojave kao uzročno povezane s lapatinibom u monoterapiji ili lapatinibom u kombinaciji s kapecitabinom, trastuzumabom ili letrozolom:
The following adverse reactions have been reported with either Twinrix or with GlaxoSmithKline monovalent hepatitis A or B vaccines:
Sljedeće su nuspojave prijavljene nakon primjene cjepiva Twinrix ili monovalentnih cjepiva protiv hepatitisa A odnosno hepatitisa B proizvođača GlaxoSmithKline:
The following adverse reactions have been reported with IONSYS during clinical studies and post marketing experience.
Sljedeće nuspojave zabilježene su sa sustavom IONSYS tijekom kliničkih ispitivanja i nakon stavljanja lijeka u promet.
The following adverse reactions have been reported with Myocet during clinical studies and post marketing experience.
Sljedeće su nuspojave prijavljene s Myocetom tijekom kliničkih ispitivanja te nakon stavljanja lijeka u promet.
The following adverse reactions have been reported with pitolisant during clinical studies enrolling more than 1094 patients in narcolepsy and other indications and are listed below as MedDRA preferred term by system organ class and frequency; frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000); within each frequency group, adverse reactions are presented in order of decreasing seriousness:
Tijekom kliničkih ispitivanja s pitolizantom u kojima je sudjelovalo više od 1094 bolesnika s narkolepsijom i drugim indikacijama, zabilježene su nuspojave navedene u nastavku prema preporučenim izrazima MedDRA-e, klasificirane po organskim sustavima i učestalosti; učestalost je definirana kao: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000); unutar svake skupine učestalosti, nuspojave su prikazane redoslijedom prema padajućoj ozbiljnosti.
The following adverse reactions in retroperitoneal or intra-abdominal surgery and in neurosurgery was common (defined as ≥ 1/100, < 1/10).
Sljedeće nuspojave pri retroperitonealnim ili intraabdominalnim kirurškim i neurokirurškim zahvatima bile su česte (definirano kao ≥ 1/100, < 1/10).
The following Adverse Reactions listed in the Table below have been accumulated in clinical studies with Axura and since its introduction in the market.
Sljedeće nuspojave koje su prikupljene tijekom kliničkih ispitivanja s Axurom i nakon stavljanja lijeka u promet su prikazane u tablici ispod.
The following adverse reactions listed in the Table below have been accumulated in clinical studies with memantine and since its introduction in the market.
Sljedeće nuspojave koje su prikupljene tijekom kliničkih ispitivanja s memantinom i nakon stavljanja lijeka u promet su prikazane u tabeli ispod.
The following Adverse Reactions listed in the Table below have been accumulated in clinical studies with Memantine Merz and since its introduction in the market.
Sljedeće nuspojave koje su prikupljene tijekom kliničkih ispitivanja s Memantine Merzom i nakon stavljanja lijeka u promet su prikazane u tablici ispod.
The following adverse reactions listed in the table below were observed in clinical studies or with post-marketing experience.
Sljedeće nuspojave navedene u tablici ispod zabilježene su u kliničkim studijama ili nakon stavljanja lijeka u promet.
The following adverse reactions occurred more often (≥ 1/100) than placebo, or were identified as possibly medically relevant adverse reactions (*).
Sljedeće nuspojave javile su se češće (≥ 1/100) nego uz placebo ili su prepoznate kao moguće medicinski značajne nuspojave (*).
The following adverse reactions occurred more often (≥ 1/100) than placebo, or were identified as possibly medically relevant adverse reactions in clinical trials with aripiprazole (see section 5.1).
Sljedeće nuspojave javile su se češće (≥ 1/100) nego uz placebo ili su prepoznate kao moguće medicinski značajne nuspojave u kliničkim ispitivanjima aripiprazola (vidjeti dio 5.1).
The following adverse reactions were assessed to be related with Travoprost 40 µg/mL eye drops, solution (either BAK or Polyquad- preserved) and are classified according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data).
Sljedeće su nuspojave povezane s Travoprost 40 µg/ml kapima za oko, otopinom (bilo BAK ili polikvad–konzervans) i razvrstane su prema slijedećem dogovoru: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000), vrlo rijetko (<1/10 000) ili nepoznato (ne može se procijeniti iz dostupnih podataka).
The following adverse reactions were identified in other nevirapine studies or by post-marketing surveillance but not observed in the randomised, controlled clinical study 1100.1486.
Sljedeće nuspojave prepooznate su u drugim ispitivanjima s nevirapinom ili u postmarketinškom razdoblju praćenja, ali nisu opažene u randomiziranom, kontroliranom kliničkom ispitivanju 1100.1486.
The following adverse reactions were identified in other nevirapine studies or by post-marketing surveillance but not observed in the randomised, controlled clinical study 1100.1486.
Sljedeće nuspojave prepoznate su u drugim ispitivanjima s nevirapinom ili u postmarketinškom razdoblju praćenja, ali nisu opažene u randomiziranom, kontroliranom kliničkom ispitivanju 1100.1486.
The following adverse reactions were identified prior to registration of LEMTRADA during use of alemtuzumab for the treatment of B-cell chronic lymphocytic leukaemia (B-CLL), as well as for the treatment of other disorders, generally at higher and more frequent doses (e.g.
Sljedeće su nuspojave utvrđene prije registracije lijeka LEMTRADA, tijekom primjene alemtuzumaba za liječenje B-stanične kronične limfocitne leukemije (B-KLL) kao i za liječenje drugih poremećaja, obično u većim i češćim dozama (npr.
The following adverse reactions were identified through post-marketing surveillance but not reported as drug-related in randomised controlled Phase III clinical trials (Protocols 018, 019, and 021): thrombocytopenia, suicidal ideation, suicidal behaviour (particularly in patients with a pre-existing history of psychiatric illness), hepatic failure, Stevens Johnson syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rhabdomyolysis.
Sljedeće su nuspojave otkrivene praćenjem nakon stavljanja lijeka u promet, ali nisu prijavljene kao povezane s lijekom u randomiziranim kontroliranim kliničkim ispitivanjima faze III (Protokoli 018, 019 i 021): trombocitopenija, suicidalne ideacije, suicidalno ponašanje (osobito u bolesnika s već postojećom psihijatrijskom bolešću u anamnezi), zatajenje jetre, Stevens-Johnsonov sindrom, osip izazvan lijekom uz eozinofiliju i sustavne simptome (DRESS), rabdomioliza.
The following adverse reactions were observed in a pooled analysis of the HEC and MEC studies at a greater incidence with oral aprepitant than with standard therapy or in postmarketing use:
Sljedeće nuspojave zabilježene su u skupnoj analizi kliničkih ispitivanja jako emetogene kemoterapije i umjereno emetogene kemoterapije, s većom incidencijom kod primjene peroralnog aprepitanta nego tijekom primjene standardne terapije ili nakon stavljanja lijeka u promet:
The following adverse reactions were observed in the NAPOLI-1 clinical study:
Sljedeće nuspojave zabilježene su u kliničkom ispitivanju NAPOLI-1:
The following adverse reactions were reported at a higher frequency category than in the other clinical studies:
Sljedeće su nuspojave prijavljene s većom učestalošću nego u drugim kliničkim ispitivanjima:
The following adverse reactions were reported during clinical studies and/or post-marketing use:
Sljedeće nuspojave prijavljene su tijekom kliničkih ispitivanja i/ili nakon stavljanja lijeka u promet:
The following adverse reactions were reported during clinical trials with LUMIGAN 0.3 mg/mL single-dose or in the post-marketing period.
Sljedeće nuspojave prijavljene su tijekom kliničkih ispitivanja s otopinom jednodoznog LUMIGAN- a 0,3 mg/ml ili nakon stavljanja lijeka u promet.
The following adverse reactions were reported in controlled clinical studies at the recommended dose of 2 mg with frequencies corresponding to very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000) and not known (cannot be estimated from available data).
Sljedeće nuspojave zabilježene su u kontroliranim kliničkim ispitivanjima preporučene doze od 2 mg učestalošću koja odgovara sljedećim kategorijama: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000) i vrlo rijetko (< 1/10 000), te nepoznato (ne može se procijeniti iz dostupnih podataka).
The following adverse reactions were reported in controlled clinical studies at the recommended dose of 2 mg with frequencies corresponding to very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000) and not known (cannot be estimated from the available data).
Sljedeće nuspojave zabilježene su u kontroliranim kliničkim ispitivanjima preporučene doze od 2 mg učestalošću koja odgovara sljedećim kategorijama: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000) i vrlo rijetko (< 1/10 000), te nepoznato (ne može se procijeniti iz dostupnih podataka).
The following adverse reactions were reported in patients in the Tasigna clinical studies at a frequency of less than 5%.
Sljedeće nuspojave prijavljene su u bolesnika u kliničkim ispitivanjima s Tasignom s učestalošću manjom od 5%.
The following adverse reactions were reported in patients treated with alirocumab in pooled controlled studies:
Sljedeće su nuspojave prijavljene u bolesnika liječenih alirokumabom u objedinjenim podacima iz kontroliranih ispitivanja:
The following adverse reactions were reported in placebo controlled trials where subjects received anaesthesia and/or neuromuscular blocking agents (1,078 subject exposures to sugammadex versus 544 to placebo):
Sljedeće nuspojave prijavljene su u placebom kontroliranim ispitivanjima u kojima su ispitanici primali anesteziju i/ili neuromuskularne blokatore (1078 ispitanika primilo je sugamadeks naspram 544 koji su primili placebo):
The following adverse reactions were reported in the Tasigna Phase III study at a frequency of less than 5%.
Sljedeće nuspojave prijavljene su u ispitivanju faze III s Tasignom s učestalošću manjom od 5%.
The following adverse reactions, considered to be possibly or probably related to the administration of ONIVYDE, were reported in 264 patients with metastatic adenocarcinoma of the pancreas, 147 of whom received ONIVYDE monotherapy (120 mg/m2) and 117 received ONIVYDE (80 mg/m2) in combination with 5-FU/LV.
Sljedeće nuspojave za koje se smatra da su moguće ili vjerojatno povezane s primjenom lijeka ONIVYDE zabilježene su u 264 bolesnika s metastatskim adenokarcinomom gušterače, od kojih je 147 primalo ONIVYDE kao monoterapiju (120 mg/m2), a 117 je primalo ONIVYDE (80 mg/m2) u kombinaciji sa 5-FU/LV.
The following adverse reactions, excluding laboratory abnormalities, were reported in patients in SPRYCEL clinical studies and post-marketing experience (Table 2).
Sljedeće su nuspojave, osim promjena u laboratorijskim nalazima, bile prijavljene u bolesnika uključenih u klinička ispitivanja lijeka SPRYCEL i iskustvo nakon stavljanja lijeka u promet (Tablica 2).
The following adverse reactions, listed below in Table 1, have been accumulated in patients with Alzheimer’s dementia treated with Exelon.
Sljedeće nuspojave, navedene u Tablici 1, prikupljene su u bolesnika s Alzheimerovom demencijom liječenih Exelonom.
The following adverse reactions, listed below in Table 1, have been accumulated in patients with Alzheimer’s dementia treated with Prometax.
Sljedeće nuspojave, navedene u Tablici 1, prikupljene su u bolesnika s Alzheimerovom demencijom liječenih Prometaxom.
The following adverse reactions, listed below in Table 1, have been accumulated in patients with Alzheimer’s dementia treated with rivastigmine.
Sljedeće nuspojave navedene ispod u Tablici 1 prikupljene su u bolesnika s Alzheimerovom demencijom liječenih rivastigminom.
The following adverse reactions, listed below in Table 1, have been accumulated in patients with Alzheimer’s dementia treated with rivastigmine.
Sljedeće nuspojave, navedene ispod u Tablici 1, prikupljene su u bolesnika s Alzheimerovom demencijom liječenih rivastigminom.
The following adverse reactions, listed below in Table 1, have been accumulated in patients with Alzheimer’s dementia treated with rivastigmine.
Sljedeće nuspojave, navedene u Tablici 1, prikupljene su u bolesnika s Alzheimerovom demencijom liječenih rivastigminom.
The following adverse reactions, listed in Table 1, have been accumulated both from a pooled data of eleven double-blind clinical trials consisting of 3230 patients (1810 treated with Corbilta or entacapone combined with levodopa/DDC inhibitor, and 1420 treated with placebo combined with levodopa/DDC inhibitor or cabergoline combined with levodopa/ DDC inhibitor), and from the post- marketing data since the introduction of entacapone into the market for the combination use of entacapone with levodopa/DDC inhibitor.
Sljedeće nuspojave, navedene u Tablici 1, prikupljene su i iz objedinjenih podataka jedanaest dvostruko slijepih kliničkih ispitivanja u kojima su bila uključena 3230 bolesnika (1810 liječenih Corbiltom ili entakaponom u kombinaciji s levodopom/DDC-inhibitorom, i 1420 liječenih placebom u kombinaciji s levodopom/DDC-inhibitorom ili kabergolinom u kombinaciji s levodopom/DDC- inhibitorom) i iz podataka dobivenih nakon stavljanja entakapona na tržište za njegovu kombiniranu primjenu s levodopom/DDC-inhibitorom.
The following adverse reactions, listed in Table 1, have been accumulated both from a pooled data of eleven double-blind clinical trials consisting of 3230 patients (1810 treated with Levodopa/Carbidopa/Entacapone Orion or entacapone combined with levodopa/DDC inhibitor, and 1420 treated with placebo combined with levodopa/DDC inhibitor or cabergoline combined with levodopa/ DDC inhibitor), and from the post-marketing data since the introduction of entacapone into the market for the combination use of entacapone with levodopa/DDC inhibitor.
Sljedeće nuspojave, navedene u Tablici 1, prikupljene su i iz objedinjenih podataka jedanaest dvostruko slijepih kliničkih ispitivanja u kojima su bila uključena 3230 bolesnika (1810 liječenih Levodopa/Carbidopa/Entacapone Orionom ili entakaponom u kombinaciji s levodopom/DDC- inhibitorom, i 1420 liječenih placebom u kombinaciji s levodopom/DDC-inhibitorom ili kabergolinom u kombinaciji s levodopom/DDC-inhibitorom) i iz podataka dobivenih nakon stavljanja entakapona na tržište za njegovu kombiniranu primjenu s levodopom/DDC-inhibitorom.
The following adverse reactions, listed in Table 1, have been accumulated both from a pooled data of eleven double-blind clinical trials consisting of 3230 patients (1810 treated with Stalevo or entacapone combined with levodopa/DDC inhibitor, and 1420 treated with placebo combined with levodopa/DDC inhibitor or cabergoline combined with levodopa/ DDC inhibitor), and from the post- marketing data since the introduction of entacapone into the market for the combination use of entacapone with levodopa/DDC inhibitor.
Sljedeće nuspojave, navedene u Tablici 1, prikupljene su i iz objedinjenih podataka jedanaest dvostruko slijepih kliničkih ispitivanja u kojima su bila uključena 3230 bolesnika (1810 liječenih Stalevom ili entakaponom u kombinaciji s levodopom/DDC-inhibitorom, i 1420 liječenih placebom u kombinaciji s levodopom/DDC-inhibitorom ili kabergolinom u kombinaciji s levodopom/DDC- inhibitorom) i iz podataka dobivenih nakon stavljanja entakapona na tržište za njegovu kombiniranu primjenu s levodopom/DDC-inhibitorom.
The following adverse reactions, listed in Table 1, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with 4 mg zoledronic acid:
Sljedeće nuspojave navedene u tablici 1 prikupljene su iz kliničkih ispitivanja i prijava nakon stavljanja lijeka u promet, uglavnom kod kroničnog liječenja 4 mg zoledronatnom kiselinom:
The following adverse reactions, listed in Table 1, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with 4 mg zoledronic acid:
Sljedeće nuspojave navedene u tablici 1 prikupljene su iz kliničkih ispitivanja i prijava nakon stavljanja lijeka u promet, uglavnom kod kroničnog liječenja s 5 mg zoledronatne kiseline:
The following adverse reactions, listed in Table 1, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with 4 mg zoledronic acid:
Sljedeće nuspojave, navedene u tablici 1, prikupljene su iz kliničkih ispitivanja i prijava nakon stavljanja lijeka u promet, uglavnom kod kroničnog liječenja s 4 mg zoledronatne kiseline:
The following adverse reactions, listed in Table 1, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with zoledronic acid:
Sljedeće nuspojave navedene u tablici 1 prikupljene su iz kliničkih ispitivanja i prijava nakon stavljanja lijeka u promet, uglavnom kod kroničnog liječenja zoledronatnom kiselinom:
The following adverse reactions, listed in table 1, have been accumulated from clinical trials with Spectrila in 125 children with newly diagnosed acute lymphoblastic leukaemia as well as post- marketing experience with other E. coli-derived asparaginase preparations in children and adults.
Sljedeće nuspojave, navedene u tablici 1, prikupljene su u kliničkim ispitivanjima Spectrile u 125 djece s novodijagnosticiranom akutnom limfoblastičnom leukemijom te iz iskustva u djece i odraslih s drugim pripravcima asparaginaze dobivene iz E. coli poslije njihova stavljanja na tržište.
The following adverse reactions, listed in Table 2, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with 4 mg zoledronic acid:
Sljedeće nuspojave navedene u tablici 1 prikupljene su iz kliničkih ispitivanja i prijava nakon stavljanja lijeka u promet, uglavnom kod kroničnog liječenja s 4 mg zoledronatne kiseline:
The following adverse reactions, listed in Table 2, have been accumulated from clinical studies and post-marketing reports following predominantly chronic treatment with zoledronic acid:
Sljedeće nuspojave navedene u tablici 2 prikupljene su iz kliničkih ispitivanja i prijava nakon stavljanja lijeka u promet, uglavnom kod kroničnog liječenja zoledronatnom kiselinom:
The following advice only refers to missed white active tablets. if you are less than 12 hours late in taking a tablet, the reliability of the pill is maintained.
Sljedeći savjeti odnose se samo na propuštene bijele tablete s djelatnim tvarima: ako kasnite s uzimanjem tablete manje od 12 sati, pouzdanost pilule je održana.
The following advice only refers to missed white active tablets. if you are less than 24 hours late in taking a tablet, the reliability of the pill is maintained.
Sljedeći savjeti odnose se samo na propuštene bijele tablete s djelatnim tvarima: ako kasnite s uzimanjem tablete manje od 24 sata, pouzdanost pilule je održana.
The following age groups will be used:
Koristit će se sljedeće dobne skupine:
The following age groups will be used: < 2 years, 2-8 years,
Koristit će se sljedeće dobne skupine: < 2 godine, 2-8 godina,
The following age groups will be used: < 2 years, 2-8 years, > 9 years.
Rabit će se sljedeće dobne skupine: < 2 godine, 2-8 godina, > 9 godina.
The following age-adjusted dosing prophylaxis regimen is recommended for infants 0 - 12 months of age (see Section 5.2 for exposure simulation):
Kod prevencije gripe za dojenčad u dobi od 0 – 12 mjeseci preporučeno je sljedeće doziranje (vidjeti dio 5.2 za simulaciju izloženosti virusu):
The following age-adjusted dosing prophylaxis regimen is recommended for infants 0 – 12 months of age:
Kod prevencije gripe za dojenčad mlađu od 1 godine preporučena su sljedeća doziranja prilagođena dobi:
The following age-adjusted dosing prophylaxis regimen is recommended for infants 0 – 12 months of age:
Kod prevencije gripe za dojenčad u dobi od 0 do 12 mjeseci godine preporučuju se sljedeća doziranja prilagođena dobi:
The following age-adjusted dosing prophylaxis regimen is recommended for infants 0 – 12 months of age:
Kod prevencije gripe za dojenčad u dobi od 0 do 12 mjeseci preporučuju se sljedeća doziranja prilagođena dobi:
The following agents may enhance the hypoglycaemic effect of nateglinide: angiotensin-converting enzyme inhibitors (ACEI), non-steroidal anti-inflammatory agents, salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents and anabolic hormones (e.g. methandrostenolone).
Sljedeće tvari mogu pojačati hipoglikemijski učinak nateglinida: inhibitori angiotenzin- konvertirajućeg enzima (ACEI), nesteroidne protuupalne tvari, salicilati, inhibitori monoaminooksidaze, neselektivni beta-adrenergični blokatori i anabolički hormoni (npr. metandrostenolon).
The following agents may reduce the hypoglycaemic effect of nateglinide: diuretics, corticosteroids, beta2 agonists, somatropin, somatostatin analogues (e.g. lanreotide, octreotide), rifampin, phenytoin and St John’s wort.
Sljedeće tvari mogu smanjiti hipoglikemijski učinak nateglinida: diuretici, kortikosteroidi, agonisti beta-2-adrenergičkih receptora, somatropin, analozi somatostatina (npr. lanreotid, oktreotid), rifampin, fenitoin i gospina trava.
The following application-site drug-related adverse reactions were reported during clinical studies in patients with KS.
Sljedeće nuspojave na mjestu primjene povezane s lijekom bile su zabilježene u kliničkim ispitivanjima u bolesnika s KS.
The following are adverse reactions reported in patients receiving fosaprepitant in clinical studies or postmarketing that have not been reported with aprepitant as described above:
Sljedeće klinički značajne nuspojave zabilježene su u bolesnika koji su primali fosaprepitant u kliničkim ispitivanjima kao i u razdoblju nakon stavljanja lijeka u promet, a koje nisu zabilježene uz primjenu aprepitanta i već navedene u prethodnoj tablici:
The following are all ADRs that were reported with paliperidone by frequency category estimated from TREVICTA and 1-monthly paliperidone palmitate injectable clinical trials.
U daljnjem tekstu navedene su sve nuspojave zabilježene s paliperidonom, prema kategoriji učestalosti koje su procijenjene u kliničkim ispitivanjima s lijekom TREVICTA i paliperidonpalmitatom u obliku 1-mjesečne injekcije.
The following are all ADRs that were reported with paliperidone by frequency category estimated from Xeplion clinical trials.
U daljnjem tekstu navedene su sve nuspojave zabilježene s paliperidonom, prema kategoriji učestalosti koje su procijenjene u kliničkim ispitivanjima s lijekom Xeplion.